Edwards, JenaValve claim US FTC's theories of harm are 'legally unprecedented'
Cardiac device inventors Edwards Lifesciences and JenaValve Technology told a US district court that the Federal Trade Commission’s challenge to Edwards’ planned acquisition of JenaValve is based on “three theories of...To view the full article, register now.
Already a subscriber? Click here to view full article